CD8A and influenza: Similar to these findings, a safety and efficacy clinical trial testing a six fluorocarbon-modified 35-mer peptide encapsulating multiple CD4+/CD8+ T cell epitopes against pan-influenza showed significant T cell-specific responses and acceptable safety profiles in the majority of test subjects [78].